HOME >> BIOLOGY >> NEWS
AVAX Technologies receives an additional $3.0 Million (AUD) investment in Australian joint venture from Australian Vaccine Technologies Ltd.

Kansas City, MO, April 6, 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced that its Australian joint venture, AVAX Australia Pty. Ltd. has received an additional $3.0 million (AUD) investment from Neptunus International Holdings Limited (NIHL), which was recently renamed Australian Vaccine Technologies Ltd. (AVT). AVAX Australia holds the rights to manufacture and market AVAX Technologies' autologous cancer vaccine (AC Vaccine™) for melanoma, M-Vax™, in Australia and has similar rights in New Zealand. M-Vax is AVAX's lead cancer vaccine and is currently being evaluated in the U.S. in a multicenter pivotal registration trial for Stage III melanoma and in a Phase 2 trial for Stage IV melanoma.

Under the joint venture agreement, AVAX Australia has now received a total of $7.0 million (AUD) from AVT for a 35% interest in the joint venture entity. AVT also has the option to purchase an additional 15% interest for $3.0 million (AUD). Under the terms of the agreement, AVAX Technologies has been granted an option to purchase common stock equivalent to 5% of AVT's fully diluted shares. AVT began trading on the Australian Stock Exchange (ASX) under the symbol "AVT" on March 10, 2000.

Jeffrey M. Jonas, M.D., President and CEO of AVAX Technologies, Inc., stated, "We are very pleased to see AVT increasing their investment in our promising joint venture in Australia. This additional capital investment represents their enthusiasm for the potential of our product and our marketing strategy. We continue to believe that the Australian market allows us to truly demonstrate the validity of our business model and our ability to effectively market individualized product."

In 1999, AVAX announced that it had received notice from Australia's Therapeutic Goods Administration (TGA) that M-Vax may be made available for commercial sale, subject only to licensure of a manufacturing facility. M-Vax, a therapeutic cancer vacc
'"/>

Contact: Olga Fleming
ofleming@cpronline.com
201-641-2408 ext. 34
AVAX Technologies, Inc.
5-Apr-2000


Page: 1 2

Related biology news :

1. Regeneration Technologies introduces advancements at AAOS
2. Palatin Technologies PT-141 increases sexual behavior in female animals
3. NASA Materials Conference Features Science Results, Experts on Technologies for Exploration
4. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
5. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
6. AVAX Technologies AC Vaccine™ improves relapse-free survival
7. AVAX Technologies M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma
8. First International Congress on Telehealth and Multimedia Technologies Story Ideas
9. Technologies Track, Map Fish Behavior
10. USGS Contributions Enhance Public Health Research, Scientists Showcase Technologies At San Diego Meeting
11. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/7/2018)... , ... November 07, 2018 , ... ... Barb Geiger, a senior Clinical Operations professional with extensive experience in clinical trial ... the US, Australia, Latin America, Europe, and Asia, has joined the firm as ...
(Date:11/6/2018)... ... ... uBiome, the leader in microbial genomics, today announced the appointment of Joseph DeRisi, ... and Co-President of Chan Zuckerberg Biohub, to its Board of Directors. , “Joe ... that he is expanding his role as a member of our board of directors,” ...
(Date:11/3/2018)... ... November 01, 2018 , ... Emerging Trends in Medical Device ... **Presented by FDAnews**, Dec. 6, 2018 – Kleinfeld, Kaplan & Becker, LLP • ... Emerging Trends in Medical Device Regulation and Quality ends on Thursday, Nov. 8. ...
Breaking Biology News(10 mins):
(Date:10/18/2018)... HAYWARD, Calif. (PRWEB) , ... October 18, 2018 ... ... its CLIA-certified genomic sequencing laboratory in the San Francisco Bay Area has received ... in quality, operations, and patient safety. , Predicine received CAP accreditation for its ...
(Date:10/17/2018)... (PRWEB) , ... October 17, 2018 , ... ... Center of Connecticut, and his associate, Dr. Michael Kang, are offering current and ... and crown lengthening results thanks to the emerging, proven treatment technology known as ...
(Date:10/17/2018)... ... October 17, 2018 , ... PathSensors’ cutting-edge CANARY based ... by USDA’s Animal and Plant Health Inspection Service for use in regulatory diagnostics. ... and trust, knowing they will be able to rapidly and accurately test and ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... the first Congressional briefing on a revolutionary technology that effectively treats pain, reduces ... of Infinity Healing, testified on how technology using photobiomodulation (PBM) has been effective ...
Breaking Biology Technology:
Cached News: